Viela Bio (NASDAQ:VIE) collaborates with Mitsubishi Tanabe Pharma (OTCPK:MTZPY)
to develop and commercialize inebilizumab – Viela’s humanized anti-CD19
monoclonal antibody in nine Asia regions for neuromyelitis optica
spectrum disorder, as well as other potential future indications.
Under the terms of collaboration, Viela will
receive an up-front licensing fee of $30M as well as additional
milestone payments and payments based, in part, on sales revenue.
MTPC will be responsible for development and
commercialization of inebilizumab in Japan, Thailand, South Korea,
Indonesia, Vietnam, Malaysia, Philippines, Singapore, and Taiwan.
https://seekingalpha.com/news/3504650-viela-bio-inks-deal-mitsubishi-tanabe-pharma-develop-inebilizumab-asia
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.